The EBOVAC2 project is one of 8 projects funded under IMI Ebola+ programme that was launched in response to the Ebola virus disease outbreak. The project aims to assess the safety and efficacy of a novel prime boost preventive vaccine regimen against Ebola Virus Disease (EVD).

To expedite the development of the vaccine regimen, Phase 2 and Phase 3 trials will be carried out in parallel and therefore coordinated by two separate teams within EBOVAC1 (Phase 1 trials and Phase 2B large scale safety and immunogenicity study) and EBOVAC2 (Phase 2 trial) projects. Find out more about Phase 2.

Between them, the EBOVAC projects will assess, through phase 1, 2 trials and Phase 2B study in Europe and Africa, the safety and tolerability of the vaccine regimen in response to the urgent public health need raised by the Ebola epidemic.

Currently, there are no proven therapies to treat Ebola or vaccines to prevent infection/disease. Thus, in view of the current Ebola epidemic, on September 5th 2014, the World Health Organisation identified the progression of Ebola vaccine candidates currently in development as an urgent public health need. Several candidate vaccines are available. No vaccines have been approved for human use to prevent or treat Ebola, although several are promising in animal models (such as the vaccine regimen being proposed in the EBOVAC programme). In view of the urgency of these outbreaks, the international community is seeking to find ways to accelerate the evaluation and use of these products.

Based on the WHO recommendations, EBOVAC2 will provide data to assess the safety, immunogenicity and efficacy of a novel candidate vaccine regimen to prevent Ebola virus disease (EVD).

Find out more about the EBOVAC1 trials:

Phase 1:
Trial countries: UK and selected African countries currently unaffected by Ebola

Phase 2B large scale safety and immunogenicity study 

More information coming soon...


  • 24 September 2018

    The 6th edition of the newsletter is available here. This issue contains an interview with Inserm's BSL-4 Laboratory director, Dr. Hervé Raoul. 

  • 24 September 2018

    The 5th EBOVAC2 newsletter March 2018 is available here. This issue includes an article on the training course conducted in Burkina Faso in January 2018.

  • 17 January 2018

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 23-26 January, 2018. For more information

  • 02 January 2018

    The 4th edition of our EBOVAC2 newlsetter was released on the 21st of December 2017.

  • 27 October 2017

    The 3rd EBOVAC2 Newsletter is now available here. Our October 2017 issue includes an interview with Dr Houreratou Barry, PI of the Centre Muraz site.

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Amsteram, the Netherlands 8-10 January 2018. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research